RBC Capital analysts provided their key takeaways from Zimmer Biomet Holdings, Inc. (NYSE:ZBH) management meeting, walking away with key insights on how innovation is helping the company become a one-stop shop, how to look at 2023 based on puts and takes, M&A strategy with all deal sizes attainable, key product launches within the different segments of the business, and the integration of robotics and technology to improve top-line growth.

According to the analysts, the company has a significant focus on innovation, targeting all aspects of the patient continuum of care and building an ecosystem, which is its growing competitive advantage and positioning it for long-term success.

The company has a notable focus on M&A as part of its ongoing growth transformation phase where the analysts expect execution in 2023 and beyond.

Furthermore, the analysts mentioned that the company has a 'sizeable backlog' that is estimated at $500 million.